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Pain Perception in Patients with Eating Disorders 
STEFAN LAUTENBACHER, PHD, ANDREJS MICHAELS PAULS, MD, 
FRIEDRICH STRlAN, MD, KARL-MARTIN PIRKE, MD, AND JÜRGEN-
CHRISTIAN KRIEG, MD 
The heat pain threshold was measured with phasic and tonic stimuli under basal conditions 
and after naloxone administration in 10 anorectic and 10 bulimic patients as well as in 11 
healthy control subjects. Under both kinds of stimulation, the basal threshold values were 
elevated in the bulimic patients and in some of the anorectic patients. Naloxone did not differ 
from placebo in its effect on the pain thresholds (phasic and tonic), suggesting that a nonopioid 
mechanism was responsible for the threshold elevation found in the eating disorder patients. 
The plasma cortisol concentration was similar in the three groups and not correlated with the 
basal pain thresholds in the patients. Other indicators of dieting such as ß-hydroxybutric acid 
and triiodothyronine also showed no correlation with the basal pain thresholds. Significant 
height correlations can be interpreted as weak evidence !hat neuropathy is the cause of the 
increase in the pain threshold. 
INTRODUCTION 
A disturbed awareness of the bodily 
state including the perception of propri-
oceptive and interoceptive stimuli was al-
ready considered by Bruch (1) to be an 
important feature of anorexia nervosa. In 
subsequent studies a distortion of body 
image was demonstrated in patients with 
anorexia and bulimia nervosa. The ques-
tion remains, however, of whether this 
disturbance is caused by perceptual, cog-
nitive, or affective variables (2, 3). For the 
adjustment ofthe body image, somatosen-
sory stimuli seem to be as important as 
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visual stimulL Nevertheless, somatosen-
sory perception in patients with eating 
disorders has been studied only rarely up 
to now. In a small nurnber of experiments 
Florin and coworkers found reduced tac-
tile perception in bulimic patients and 
discussed this finding as a possible contri-
bution to the body irnage distortion of 
their patients (4, 5). Their anorectic pa-
tients did not show this deficit, but these 
subjects were only slightly underweight 
when studied (at the end of therapy). 
Pain perception and pain roernory have 
a somatotopic organization as has become 
evident by clinical research an nerve in-
juries, the outstanding exarople being the 
phantom limb (6, 7). This organization can 
be strongly influenced by reducing and 
enhancing the nociceptive input from 
special body areas (8). These observations 
have given clear evidence that a highly 
dynamic "pain body image" exists, which 
seems to contribute to the formation of 
the general body image. Therefore distor-
tions of the former produced by changes 
in pain perception may result in distor-
tions in the latter. 
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Another reason for studying the percep-
tion of nociceptive stimuli in patients 
with eating disorders is the altered opioid 
activity seen in these patients. In the con-
siderable number of studies conducted in 
the past, mainly the ß-endorphin plasma 
level has been assessed. However, the re-
sults have been inconsistent, with in-
creased, unchanged, and decreased levels 
reported for both anorexia and bulimia 
nervosa (9-15). Because the influence of 
systemic ß-endorphin on pain perception 
is far from clear (16), these contradictory 
findings do not provide a solid basis for 
making predictions about pain perception 
in patients with eating disorders. More 
useful in this context is the observation 
that patients with anorexia nervosa have 
increased CSF opioid activity (17). Despite 
this finding, to our knowledge pain per-
ception in eating disorder patients and its 
relation to opioid activity has been inves-
tigated in only one single case study: 
Abraham and Joseph (18} reported an in-
crease in pain tolerance after vomiting in 
a bulimic patient, which was accom-
panied by an increase in plasma cortisol, 
a putative marker of systemic ß-endor-
phin. After naloxone administration the 
pain tolerance level returned to normal. 
These considerations and findings point 
to a disturbed somatosensory and, espe-
cially, pain perception in eating disorder 
patients as a possible contribution to the 
distorted body image. They also suggest 
that a systematic investigation of pain per-
ception in such patients would be useful. 
Based an the assumption that an increase 
in opioid activity is responsible for the 
perceptual deficit, we studied pain per-
ception in anorectic and bulimic patients 
under basal conditions and after admin-
istration of naloxone. Ta determine the· 
effect of ß-endorphin in this context, we 
measured its putative marker, plasrna cor-
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tisol. Furtherrnore, we exarnined the re-
lation between pain perception and eating 
behavior based on assessments of meta-
bolic and endocrine indicators of dieting 
(ß-hydroxybutric acid, triiodothyronine) 
(19). 
METHOD 
Subjects 
The subjects were 10 patients with anorexia ner-
vosa, 10 palien!s wi!h bulimia nervosa, and 11 
healthy controls (all femalcs). The diagnosis of the 
eating disorder was made according to the DSM-lll-
R criteria (20) with the aid of the SCID (21). Subjects 
were cxcluded from the study if thcy bad been on 
medication for any length of time, with the excep-
tion of contraceptives. Other exclusion criteria were 
the intake of psychoactlve drugs in the previous 6 
months, alcohol dependency, or clinical evidence of 
disk disease. neuropathy, hypertension, or derma-
tosis at the point of pain stimulation. Tahle 1 shows 
that the age distribu tion was similar in all three 
groups of subjects and that the two patient groups 
did not differ in duration of illness. The anorectic 
patients were not only severely underweight but 
were also shorter than the bulimic patients and the 
controls. Seven of the anorectic patients controlled 
their weight only by fasting and three also by occa-
sional vomiting. Seven of the bulimic patients had a 
history of anorexia nervosa, and three of !he anorec-
tic patients had had bulimic episodes. In the bulimia 
group the number of binges ranged from 4 to 28 per 
week. 
Of the 20 patients participating, 18 were studied 
at the beginning of inpatient behavior therapy. The 
other two were in outpatient behavior thcrapy and 
still had bulimic symptoms at the time of investiga-
tion. No patient received drug treatment during the 
study or in the course of therapy. To control for 
menstrual variations in pain sensitivity and opioid 
activity {22, 23), the control subjects were studied 
only during the first 14 days oftheir menstrual cycle. 
This type of control was impossible in the patients 
because of oligomenorrhea or amenonhea. 
The protocol was approved by an ethics commis-
sion; all subjects gave wrilten informed consent. 
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Apparatus and Procedure 
The subjects were investigated twice, on two dif-
ferent days. at a maximum interval of 5 days. With 
the exception of drug administration, the procedure 
was identlcal on both days. Sessions started at 7:30 
a.m. with collection of a blood sample. After 30 
minutes pain thresholds were assessed for the first 
time. The duration of pain threshold measurement 
was approximately 20 minutes. Drug administration 
followed: 100 ml saline either with or without 5 mg 
naloxone (Narcanti9) intravenously. Pain thresholds 
were determined for the second time 30 minutes 
after the administration. 
Naloxone and placebo were administered in a 
double-blind design. with neither the subjects nor 
the investigator of pain perception knowing which 
treatment was being used. To control for order ef-
fects, the active drug and placebo were equally dis-
tributed on days 1 and 2. For this purpose the order 
oI naloxone and placebo was randomized for the 
first half of the subjects in each group and then the 
second half were treated in the reverse order. 
Pain thresholds were assessed with heat stimuli 
according to two methods, allowing pain perception 
to be studied under both phasic and tonic stimula-
tion. (Phasic pain stimuli produce only very brief 
nociceptive stimulation, whereas tonic pain stimuli 
lead to nociceptivc stimulation of a duration long 
enougb to trigger temporal summation processes in 
pain perceplion. These processes, and not only pain 
intensity at the beginning of stimulation, are known 
tobe reduced by opiates (24) and may therefore also 
reflect the effect of endogonous opioids.) Phasic and 
tonic pain thresholds were measured with the help 
of the programs SCHMERZ 1 and SCHMERZ 2, 
which are part of the pain and thermal sensitivity 
diagnosis unit PATH-Tester MPI 100 (Phywe Sys-
teme GmbH). This computer-controlled unit pro-
duces thermal stimuli by a Peltier thermode (stim-
ulation area: 6 cm'; contact pressure: 0.4 N/cm2). 
The phasic pain threshold was determined by hav-
ing the subjects stop a tempcrature rise of 0.7°C/s 
slarting from 36°C as soon as they feit pain. There 
were eight trials. The threshold was computed as 
the mean of the peak temperatures of the last five 
trials. The tonic pain threshold was measured with 
a modification of the "method of subjective sensiti-
zation" (for details see Refs. 25 and 26). The subjects 
bad to adjust the stimulus to the temperature of 
their pain threshold with heating and cooling but-
tons. starting from 36°C. Stimulation was then con-
tinued for 35 seconds at the temperalure adjusted. 
Changes in intensity of perception due to temporal 
summation processes during this interval were 
measured in a second stimulus adjustment proce-
dure. Six trials of this kind were conducted. The 
threshold was computed as the mean of both Stim-
ulus adjustments of the last five trials. The subjects 
sat in front of a small table, on whkh were placed 
the response panel and the signalling devices. Thcr-
mode placement was on the lateral dorsum pedis of 
the right leg. 
Treatment effects on subjective state were as-
sessed on eigbt horizontal visual analog scales with 
a length of 10 cm and a verbal descriptor at each 
end. The scales measured tiredness, headache, dry-
ness of mouth, nausea, physical discomfort, bad 
mood, sensation of warmth, and drowslness. The 
scales were administered before each pain percep-
tion measurement. 
As heat pain perception, lo a small degree, de-
pends on the basal skin temperature {27), and as 
only the small skin area under the thermode is 
heated to the preset adaptation temperature, skin 
temperature near the thermode placement was as· 
sessed by a PTlOO sensor in three readings during 
pain threshold assessment. 
Triiodothyronine (T3) and plasma cortisol were 
measured by radioimmunoassay (SERONO, Frei-
burg) as described earlier (28). Interassay variability 
was 5.6% at an average conccntration of 1.1 ng/ml 
T3 and 7.0% at an average concentration of 125 µg/ 
l cortisol. ß-hydroxybutric acid (tl-HBA) was meas-
ured according to Williamson and Mellonby (29). 
Interassay variability was 5.1 % at 0.53 µmol/ml. 
Due to procedural and technical problems, not all 
measures could be assessed in all subjects. 
Evaluation 
Two kinds of analyses of variance (MANOVA), 
each with a group factor and a repeated measure-
ment factor, were computed to determine (a) group 
differences (factor "group") and differences between 
days 1and2 (factor "day") in the basal values (before 
treatment) and (b) group differences (factor "group") 
and differences between naloxone and saline (factor 
"treatment") in the effects of treatment. The cffects 
of treatment were calculated as \he difference be-
tween the measurements before and after treatment. 
When on!y two groups were compared, t tests were 
used; the relationship between two variables was 
determined by calculalion of Pearson correlation 
coefficients. 
RESULTS 
Group Differences in the Basal Values 
For all variables that were assessed on 
both days, the basal values (values before 
drug administration) did not differ signif-
icantly between days 1 and 2 ( p > 0.05 
for all F tests for the factor "day"). 
The pain thresholds showed differences 
between the diagnostic groups (see figure 
1). The differences were significant for the 
phasic pain threshold (factor "group"; df 
2,28; F = 4.41; p = 0.022) and close to 
significant for the tonic pain threshold 
(factor "group"; df 2,28; F = 2.82; p = 
0.076). The t tests for the mean thresholds 
of days 1 and 2 revealed that the bulimic 
patients had significantly higher thresh-
olds than the controls under both phasic 
stimulation (t = 3.37; p = 0.003} and tonic 
stimulation (t = 2.46; p = 0.024). No other 
group comparison (anorexia vs. bulimia, 
anorexia vs. control) yielded a significant 
difference. Thresholds more than 2 stand-
ard deviations above the mean ofthe con-
AN BN CO 
Phasic 
AN BN CO 
Tonic 
Fig. 1. Mean and standard deviation of the basal 
pain thresholds (°CJ before drug administra-
tion (mean of days 1 and 2) for the patients 
with anorexia nervosa (AN, N = 10} and 
bulimia nervosa (BN, N = 10) and for the 
control subjecls (CO, N = 11) under phasic 
and tonic heat pain stimulation. 
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trols were found on one or both days in 
three anorectic patients and three bulimic 
patients under phasic stimulation and in 
one anorectic patient and two bulimic 
patients under tonic stimulation. Hence, 
at least some anorectic patients had ele-
vated pain thresholds. Phasic and tonic 
pain thresholds correlated with r = 0.80 
(p < 0.001) and seemed to measure the 
same aspect of pain perception under the 
conditions of this study. 
The concentration of plasma cortisol 
was similar in all three groups (factor 
"group"; df 2,27; F = 0.31; p = 0.735), with 
only slightly elevated levels in the ano-
rectic patients. Figure 2 gives the mean of 
both days and shows that there was a 
great within-variance in each group. Fur-
thermore, no significant differences were 
found for the concentration of ß-HBA (fac-
tor "group"; df 2,24; F = 1.43; p = 0.260), 
mainly because of the great variance 
within the patient groups (see Table 1). 
The T3 values, however, differed signifi-
cantly between groups (factor "group"; df 
2,27; F = 14.09; p < 0.001; see Table 1). 
(ng/ml) 
400 
380 
••• 
••• 
320 
Fig. 2. Mean and standard deviation of the basal 
plasma cortisol concenlration (ng/ml) be-
forc pain perception measurement (mean of 
days 1 and 2} for the patients with anorexia 
nervosa (AN, N = 10) and bulimia nervosa 
(BN, N = 9) and for the control subjects (CO, 
N = 11). 
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TADLE 1. Anamnestic Data, Body Measures, and Indicators of Dieting (Group Means 
and Standard Deviations) 
Patient Groups 
Anorexia Bulimia Contra! group 
nervosa nervosa (N=11) 
(N= 10) (N= 10) 
Age (years) 22.7 ± 3.7 22.4 ± 2.9 23.1 ± 3.0 
Duration of illness (years) 4.4 ± 2.8 5.2 ± 3.2 
Height (cm) 162.7 ± 4.9 172.8 ± 6.4 170.5 ± 5.4 
Weight(kg) 36.8 ± 3.0 60.3 ± 8.9 58.2 ± 2.9 
Ideal weight {%)* 66.8±6.0 95.5 ± 12.7 97.9 ± 3.9 
ß-HBA (µmol/ml) 0.31 ±0.55 0.17 ± 0.23 0.04±0.06 
T3 (ng/ml) 0.94 ± 0.21 1.19 ± 0.28 1.47 ± 0.21 
Skin temperature ("C) 27.4 ± 2.2 26.5 ± 1.1 27.0 ± 2.2 
* Computed according to the tables of the Metropolitan Life lnsurance Company (41). 
The anorectic patients bad significantly 
lower T3 values than the bulimic patients 
(t = 2.34; p = 0.032) and controls (t = 5.85; 
p < 0.001), and the values for the bulimic 
patients were also significantly lower 
than those for the controls (t = 2.53; p = 
0.021). 
The diagnostic groups did not differ in 
skin temperature (factor "group"; df 2,28; 
F = 0.54; p = 0.588; see Table 1). 
Effects of Drug Administration 
There was no difference in the effect of 
naloxone and placebo on the pain thresh-
old under either phasic or tonic stimula-
tion (factor "treatment"; phasic: df 1,28; F 
= 2.02; p = 0.166; tonic: df 1,28; F = 0.69; 
p = 0.413). The differences between the 
pain measurements before and after drug 
administration are given in Figures 3A 
and B. Moreover, there were no signifi-
cant group differences (factor "group"; 
phasic: df 2,28; F = 0.05; p = 0.953; tonic: 
df 2,26; F = 0.88; p = 0.427) or group x 
treatment interactions ("group" x "treat-
rnent"; phasic: df 2,26; F = 2.45; p = 0.105; 
tonic: df 2,28; F = 1.43; p = 0.256). Of the 
A 
Naloxone 
Placebo 
AN 
NaJoxone BN 
Plaoebo 
No,_,,. 
CO 
PJac•bo 
-· -1 0 teftlrpef'atvre tn•c 
lncreue to pre-treatm•nl lavel 
B 
NaloJl'.OM 
AN 
PlaoebO 
Naloxon• BN 
Placebo 
Na1011.one eo 
Placebo 
-· -· 0 temper•ture rn •c 
inoreaae to pre-treatment level 
Fig. 3. Mean and Standard deviation of the effects 
of the treatmenls "naloxone" and "placebo" 
(mean differences between measurements 
before and after drug administration) on the 
pain thresholds ("C} for the patients with 
anorexia nervosa (AN. N = 10} and bulimia 
nervosa (BN, N = 10) end for the control 
subjects (CO, N = 11) under phasic (A) and 
tonic (B) heat pain stimulation. 
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eight subjective state scales, only the scale 
"drowsiness" showed differences between 
naloxone and placebo (factor "treatment"; 
df 1,27; F = 4.86; p = 0.036), with higher 
values for naloxone. 
Correlations of the Pain Thresholds 
To find out which variables other than 
the diagnosis showed covariations with 
the pain thresbolds, wc computed corre-
lation coefficients for the correlations be-
tween the phasic and tonic pain thresh-
olds and tbe various basal values (before 
drug administration) for the combined 
groups of patients. (As it has been shown 
in numerous studies that anorexia ner-
vosa and bulimia nervosa are psychopath-
ologically and neurobiologically very 
closely related disorders, such a combi-
nation of the two diagnostic groups is jus-
tified for this purpose.) Table 2 shows the 
results. Only age and height correlated 
significantly with the pain thresholds. 
The endocrine and metabolic indicators 
of dieting, and the plasma cortisol concen-
T ABLE Z. Pearson Correlation Coefficients (r) 
for the Correlations of the Phasic and Tonic Pain 
Thresholds wilh the Anamnestic Data, Body 
Measures, Endocrine and Metabolie lndicators of 
Dieting (T3, ß·HBA), and Plasma Cortisol for the 
Two Patient Groups Combined (N = 20) 
Pain Threshold (r) 
Phasic Tonic 
Age 0.36 0.43* 
Duration of illness 0.10 0.23 
Weight 0.38 0.19 
Ideal weight 0.29 0.05 
Height 0.41* 0.40* 
T3 0.37 0.20 
ß-HBA -0.17 -0.10 
Plasma cortisol -0.04 0.17 
• p :5 0.05. 
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tration showed no strong relation with the 
pain thresholds. 
DISCUSSION 
In thc present study an elevation of the 
pain threshold was found in the bulimic 
patients and in at least some of the ano-
rectic patients. A furtber division of the 
anorectic patients in "only restricters" 
and "occasional vomiters" did not explain 
this difference within the anorectic group. 
Because the patients showed the known 
psychobiological indicators of their re-
spective eating disorder, wbich are spe-
cific changes in weight, ß-HBA, and T3 
(19), this result can be regarded as repre-
sentative. (As we have earlier demon-
strated that hypercortisolism in anorexia 
nervosa can rapidly reverse after hospitaI 
admission (30), the Jack of group differ-
ences in plasma cortisol levels is rather 
due to this phenomenon than to a sam-
pling bias.) The differences in pain per-
ception between the patient groups and 
the control group can hardly be explained 
by menstrual variations in the latter 
group because pain sensitivity, if it varies 
at all, does not seem to be elevated in the 
first 14 days of the menstrual cycle, the 
period of investigation in our study (22, 
23). 
The reduced pain sensitivity in the bu-
limic and in some anorectic patients is 
very likely not produced by an increased 
activity of endogenous opioids: naloxone, 
an opioid antagonist, did not change the 
pain thresholds any differently than pla-
cebo in either the patients or the controls. 
These results are similar to those which 
Stacher and coworkers (31) obtained in 
healthy subjects using the same dosage of 
naloxone (5 mg), a similar time pattern of 
administration, and also heat pain stimu-
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lation. The lack of hyperalgesia after the 
naloxone administration was probably 
not the consequence of too small a dosage 
as-especially in the underweight pa-
tients-the dosage was sufficiently high 
to cause antagonistic effects (32), and even 
in these patients no decrease in pain 
thresholds was found. Furthermore, some 
subjects reported an increase in subjec-
tive drowsiness, that is, a change in the 
subjective state, which was found in other 
studies only when much larger dosages 
were administered (17, 31). 
That the elevation in pain threshold 
was caused by increased production of 
pituitary ß-endorphin, sometimes found 
in these patients (10, 11, 13, 14), is also 
unlikely because no group differences in 
plasma cortisol concentration were ob-
served. (As ACTH and ß-endorphin are 
produced from the same precursor mole-
cule in the same cell of the anterior pitui-
tary gland and are secreted simultane-
ously under most physiological condi-
tions, we can assume that cortisol is an 
indicator of ß-endorphin release as it is 
for ACTH secretion. This parallel secre-
tion of ß-endorphin and cortisol has re-
cently confirmed by Young and cowork-
ers (33)). Moreover. the pituitary ß-endor-
phin is more involved in the mechanisms 
of stress analgesia than in the modulation 
of pain perception under basal conditions 
(16). 
The observation that phasic and tonic 
pain stimulation produced similar results 
suggests that temporal summation proc-
esses, which are involved in opiate anal-
gesia (24), were not responsible for the 
group differences. This is a further argu-
ment against the assumption of an opioid 
mechanism underlying the reduced pain 
sensitivity in anorexia and bulimia ner-
vosa. Taken together, the results of the 
present study indicate that pain percep-
tion in bulimic and some anorectic pa-
tients seems tobe reduced by a non-opioid 
mechanism. This mechanism is different 
from that described by Abraham and Jo-
seph (18): in a case study of a bulimic 
patient these authors found an increase 
in pain tolerance after vomiting that could 
be reversed by naloxone. 
One can speculate that the reduced 
pain sensitivity is of a neuropathic origin. 
Manifest forms ofperipheral neuropathies 
have been observed in some patients with 
eating disorders, but they seem to be re-
stricted to severely ill and long-term pa-
tients (34, 35). In anorexia nervosa, 
MacKenzie and coworkers (35) supposed 
malnutrition and nerve compression due 
to the loss of protective tissue to be the 
causes. However, the unbalanced andre-
stricted nutrition in eating disorder pa-
tients might also lead to more subclinical 
forms of deficiency neuropathies. There 
is some evidence that the intake of vita-
mins is reduced and that the intracellular 
stores of some B vitamins are depleted 
(36). The lack of B vitamins can cause 
neuropathies with sensibility dysfunc-
tions (37). Furthermore, drug and alcohol 
abuse is often found in bulimic patients 
(38), and this too can produce neuropathic 
dysfunctions of sensibility. Assuming that 
a subclinical neuropathy is the mecha-
nism underlying the reduced pain sensi-
tivity, the observed correlation between 
pain thresholds and height can be ex-
plained by the fact that the susceptibility 
of the peripheral nerves to metabolic or 
toxic damages depends on their length. 
Therefore, metabolic and toxic neuropa-
thies typically produce symptoms in a 
distal-proximal order (39). Consequently, 
in diabetic neuropathy a relation between 
neuropathic symptoms and height was 
found (40). The findings of Florin and 
coworkers (4, 5) that tactile sensibility as 
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weil is reduced in bulimic patients are 
compatible with the hypothesis of a neu-
ropathic dysfunction of cutaneous sensi-
bility. This hypothesis needs tobe tested 
in an investigation of further modalities 
of cutaneous sensibility that are estab-
lished indicators of specific neuropathic 
disorders. 
The present study demonstrated that 
reduced pain sensitivity occurs in bulimic 
patients and in some anorectic patients. 
Still tobe determined is whether this dys-
function leads to an impairment of symp-
tom perception or, as part of a general 
reduction in somatosensory perception, 
also contributes to the well-known distor-
tion of the body image. 
SUMMARY 
Past findings of body image distortions 
as a possible consequence of disturbed 
somatosensory processing and of changes 
in opioid activity in patients with an-
orexia and bulimia nervosa marle an in-
vestigation of pain perception in such pa-
tients appear useful. We studied heat pain 
thresholds with phasic (short) and tonic 
(prolonged) stimuli before and after ad-
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